|
|
|
||
|
In Haematology and Oncology course students learn basics of epidemiology, pathogenesis, diagnostics, staging and therapy of both solid tumours and hematological malignancies as well as non-malignant hematological disorders. Theoretical introduction in form of lectures, that provides an overview of crucial topics in the subject, are followed by seminars that provide more detailed insight into respective diseases, their taxonomy, special pathology, diagnostics, clinical course and treatment. During the seminars on non-malignant hematology students learn basics of hematology laboratory practice, both morphology and coagulation part, with laboratory results inerpretation and basics of rational hemotherapy (transfusiology). At the practical lectures students are examining patients with particular malignant diseases. Haematooncological part of practical lectures are focused on case studies with differential diagnosis and treatment. The access to patients with haematological malignancies is limited because of deep immunosupression in most of them, but whenever it is possible, patients with clear signs of haematological disease, especially with lymphadenopathy and splenomegaly, are demonstrated to the students. In the oncological and haematooncological part of the course students learn basics of therapy of tumorous diseases according to the evidence based medicine, innovation in biological therapy and basics of modern supportive and paliative care.
Preventive care and early diagnosis principals of both malignant and non- malignant haematologic diseases will be also mentioned.
Last update: Kozák Tomáš, prof. MUDr., Ph.D. (06.01.2016)
|
|
||
|
The aim of the subject will be to give students basic knowledge of management of neoplasias and also non malignant diaseases of blood. Students will be introduced to epidemiology, clinical signs, staging and basdics of treatment of soild tumors as well as non-malignant hematology disorders. The course will also enable to gain practical skills in communication with an oncology patient. Last update: Kozák Tomáš, prof. MUDr., Ph.D. (10.02.2012)
|
|
||
|
Haematology part: Hoffbrand V.A., Moss P.A.H: Hoffbrand´s Essential Haematology, 7. edition, Wiley Blackwell, 2015
Last update: Kozák Tomáš, prof. MUDr., Ph.D. (22.09.2019)
|
|
||
|
Lectures, seminars, practice at the respective department Last update: Kozák Tomáš, prof. MUDr., Ph.D. (10.02.2012)
|
|
||
|
Credits will be given to student providing he/she meets following two conditons: 1. active presence at both semminars and practical lectures. 2. successful completion of the credit test (20 questions), the credit test will be submitted tu the student at the very last practical lecture of the subject. The students are strongly encoureged to attend also main lectures of the subject as these provide an introduction to the cruicial topics of the subjects and e.g. up to date information on new treatment strategies and aproaches. Final exam: will be done after the end of the summer semester by test containing 50 questions covering clinical oncology, haematology, haematooncology (topics of the questions see bellow). Questions from pathology, pathophysiology and pharmacology related to clinical topics will be also part of the test. Just one from the possible answers will be correct. One point is earned for each correctly answered question. Scale of the success is following: A: 46 and more correctly answered questions, B: 41-45 correctly enswered questions, C: 36-40 correctly answered questions, D: 35 and less correctly answered questions. Students who do not succesfuly pass 1st and 2nd attempt will be examined in form of oral examination at the 3rd term. To be eligible for final exam the student must have passed the exam from General Foundations of Pathology and Pathophysiology (CVSE3P0011). Terms for final exam tests will be posted in time in SIS (EXAM DATES)
Topics HAEMONC for final exam 3. year, general medicine, 2023/2024
Topics – Oncology School year 2024/2025
Topics Heamatology/Haematooncology for the final exam, school year 2024/2025, general medicine 1. Laboratory examination in haematology 2. Morfological classification of anaemia 3. Iron defficiency anaemia 4. Pernicious anaemia 5. AIHA 6. TTP/HUS 7. Thalassemia and sicle cell disease 8. PNH 9. Hereditary spherocytosis and G-6-P-D deficiency 10. Aplastic anaemia 11. Neutrophilia and its causes 12. Neutropenia and its causes 13. Eosinophilia and its causes 14. Lymphocytosis and its causes 15. Thrombocytopenia: causes and 16. ITP 17. Thrombocytosis and its causes 18. Thrombocytopathy 19. Acute myeloid leukaemia (AML) 20. Acute lymphoblastic leukaemia (ALL) 21. Chronic myelogenous leukaemia (CML) 22. Primary (idiopathic) myelofibrosis (PMF) 23. Polycythaemia vera 24. Essential thrombocytaemia (ET) 25. Chronic lymphocytic leukaemia (CLL) 26. Lymphoma classification and staging 27. Hodgkin's lymphoma (HL) 28. Diffuse large B cell lymphoma (DLBCL) 29. Mantle cell lymphoma (MCL) 30. Follicular lymphoma (FL) 31. Burkitt's lymphoma (BL) 32. Marginal zone lymphoma (MZL) 33. Waldenström's macroglobulinaemia 34. T- cell lymphoma 35. MGUS 36. Multiple myeloma 37. Alkylating agents, antimetabolites and topoisomerase inhibitors in the treatment of neoplastic diseases F 38. Anthracyclins, platinating agents, nukleoside analogs in the treatment of neoplastic diseases F 39. Corticosteroids in the treatment of neoplastic diseases F 40. Targetted („biological“) therapy in hematooncology F 41. Supportive care in hematooncology, treatment of pain F 42. Hemophilia 43. Von Willebrand's disease 44. Anticoagulation treatment. Heparin, Warfarin and new oral anticoagulants F 45. Antiaggregation treatment F 46. DIC 47. Thrombosis a thrombophilia 48. Antiphospholipid syndrome, lupus anticoagulans 49. Blood products, indication for transfusion and complications 50. Blood derivatives, indication to administration, complications
Last update: Kozák Tomáš, prof. MUDr., Ph.D. (24.02.2025)
|
|
||
|
Syllabus HEMONK 2019/2020
Last update: Kozák Tomáš, prof. MUDr., Ph.D. (22.09.2019)
|